Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Abstract Introduction Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs) with guselkumab in patients with active psoriatic...

Full description

Bibliographic Details
Main Authors: Jeffrey R. Curtis, Atul Deodhar, Enrique R. Soriano, Emmanouil Rampakakis, May Shawi, Natalie J. Shiff, Chenglong Han, William Tillett, Dafna D. Gladman
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-09-01
Series:Rheumatology and Therapy
Subjects:
Disease activity
Fatigue
Guselkumab
Joint disease
Minimal clinically meaningful improvement
Pain
Online Access:https://doi.org/10.1007/s40744-024-00702-0

Internet

https://doi.org/10.1007/s40744-024-00702-0

Similar Items